{"analyses":[{"ciLowerLimit":"0.3307","ciNumSides":"TWO_SIDED","ciPctValue":"95.03","ciUpperLimit":"0.7299","estimateComment":"A hazard ratio \\<1 favours AZD9291.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0004","paramType":"Hazard Ratio (HR)","paramValue":"0.4913","statisticalComment":"Determined using a log rank test stratified by stage, race and mutation type.","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"Insufficient OS events to estimate median and 95% confidence interval (Kaplan Meier analysis)","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Insufficient OS events to estimate median and 95% confidence interval (Kaplan Meier analysis)","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"233"},{"groupId":"OG001","value":"237"}],"units":"Participants"}],"description":"Defined as the time from the date of randomization until date of death due to any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Taken once daily","id":"OG000","title":"AZD9291 80mg Tablet"},{"description":"Taken once daily","id":"OG001","title":"Placebo Tablet"}],"paramType":"MEDIAN","populationDescription":"Full Analysis Set (FAS) stage IIA-IIIA patients","reportingStatus":"POSTED","timeFrame":"Up to approximately 7 years after the first patient is randomized (maximum follow up of 86 months)","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}